Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U, Masini C, Baldessari C, Naglieri E, Caserta C, Manacorda S, Maruzzo M, Milella M, Buttigliero C, Tambaro R, Ermacora P, Morelli F, Nolè F, Astolfi C, Sternberg CN. Fornarini G, et al. Among authors: tambaro r. ESMO Open. 2021 Jun;6(3):100118. doi: 10.1016/j.esmoop.2021.100118. Epub 2021 May 10. ESMO Open. 2021. PMID: 33984678 Free PMC article.
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer.
Leopardo D, Cecere SC, Di Napoli M, Cavaliere C, Pisano C, Striano S, Marra L, Menna L, Claudio L, Perdonà S, Setola S, Berretta M, Franco R, Tambaro R, Pignata S, Facchini G. Leopardo D, et al. Among authors: tambaro r. Eur Rev Med Pharmacol Sci. 2013 Aug;17(16):2145-58. Eur Rev Med Pharmacol Sci. 2013. PMID: 23893180 Free article. Review.
Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M, Attademo L, Arenare L, Spina A, Russo D, Califano D, Losito NS, Setola SV, Franzese E, De Vita F, Orditura M, Pignata S. Ventriglia J, et al. Among authors: tambaro r. Int J Gynecol Cancer. 2021 Jan;31(1):110-113. doi: 10.1136/ijgc-2020-001540. Epub 2020 Aug 12. Int J Gynecol Cancer. 2021. PMID: 32796087
60 results